evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,429 questions · 3,558 findings · 436 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 660 · 18.5%GRADE not reported 375 · 10.5%Very low 727 · 20.4%Low 887 · 24.9%Moderate 709 · 19.9%High 200 · 5.6%

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review

Systemic corticosteroids vs placebo or control

Mortality Mortality at latest · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Systemic corticosteroids vs placebo or control

Death or cerebral palsy · preterm infants with chronic lung disease

Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).

1 finding from 1 review

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs usual care

Change in arterial partial pressure of oxygen · stable COPD
2 findings from 1 review

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs standard treatment following a severe exacerbation

Change in arterial partial pressure of oxygen · post‐exacerbation COPD
2 findings from 1 review

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs standard treatment following a severe exacerbation

Change in arterial partial pressure of carbon dioxide · post‐exacerbation COPD
2 findings from 1 review

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs standard treatment following a severe exacerbation

Change in the health‐related quality of life · post‐exacerbation COPD
2 findings from 1 review

Summary of Findings Table ‐ Chronic non‐invasive ventilation vs standard treatment following a severe exacerbation

Admission‐free survival · post‐exacerbation COPD

Summary of Findings Table ‐ Chronic non‐invasive ventilation may leads to lower admission‐free survival compared with standard treatment following a severe exacerbation (low certainty).

1 finding from 1 review